SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Preventive Visit — Pierre Le Moyne d'Iberville — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientPierre Le Moyne d'Iberville
Date of birth1661-07-16
IdentifiersMRN HR-ET014-SYN-TD; SSN (made up) 000-14-7260
Document date1705-04-21
AuthorMarguerite Delacroix-Boateng, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Periodic adult preventive visit. [S]

History of Present Illness

Mr. Le Moyne d'Iberville is a 43-year-old naval commander treated seven weeks ago with chloroquine and primaquine for relapsing P. vivax malaria, who comes for a preventive visit. He has had no fever, chills or sweats since the treatment and no dark urine. He carries his fever card. He is preparing a squadron that is expected to sail early next year for French Guiana and the French Antilles, and his pre-travel vaccines are planned for the summer visit. He walks the dockyard most days and sleeps about seven hours. He wants his prevention brought up to date before the deployment. [S]

ElementDetail
VisitPeriodic adult preventive visit, age 43
MalariaNo fever since chloroquine and primaquine
DeploymentExpected to sail early next year
MoodPHQ-2 0
AlcoholAUDIT-C 3

Health risk assessment. Completed by the patient on paper in the waiting room and reviewed with him face to face by Dr. Delacroix-Boateng. [S]

DomainFinding
Self-rated healthGood since the malaria treatment
PsychosocialBusy and under pressure preparing the squadron; supportive household
TobaccoNever
AlcoholWine with dinner, about eight drinks a week; AUDIT-C 3
Physical activityWalks the dockyard most days; sails
NutritionRegular meals; fish and bread, few vegetables
SleepAbout seven hours
Sexual healthNo concerns; one partner
SafetyWorks on ladders and rigging in the dockyard; can swim
Road safetyWears a seat belt
Activities of daily livingIndependent
Hearing and visionHearing normal by his report; reads without glasses

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever, chills, night sweats, or weight loss
EyesNegativeNo change in vision
Ears, nose, mouth, and throatNegativeNo hearing change or dental pain
CardiovascularNegativeNo chest pain or palpitations
RespiratoryNegativeNo cough or breathlessness
GastrointestinalNegativeNo abdominal pain, jaundice, or change in bowel habit
GenitourinaryNegativeNo dark urine or urinary symptoms
MusculoskeletalNegativeNo joint pain
IntegumentaryNegativeNo rashes or changing moles
NeurologicalNegativeNo headache or numbness
PsychiatricNegativeMood good; PHQ-2 score 0

11 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Chloroquine phosphate 500 mg tablet: 1,000 mg (two tablets) at once, then 500 mg at 6, 24 and 48 hours; take with food1,000 mg, then 500 mg at 6, 24 and 48 hours (2,500 mg salt in total)Oral route1705-03-03 to 1705-03-05completedS
Primaquine phosphate 26.3 mg tablet (15 mg base): two tablets (30 mg base) by mouth daily with food for 14 days30 mg base once daily for 14 daysOral route1705-03-03 to 1705-03-16completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1705-04-21Body height175cmS
1705-04-21Body weight69.2kgS
1705-04-21Body mass index (BMI) [Ratio]22.6kg/m2S
1705-04-21Systolic blood pressure120mm[Hg]S
1705-04-21Diastolic blood pressure76mm[Hg]S
1705-04-21Heart rate64/minS
1705-04-21Respiratory rate14/minS
1705-04-21Body temperature36.6CelS
1705-04-21Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1705-04-21Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
1705-04-21Total score [AUDIT-C]3{score}S
1705-04-21Cholesterol [Mass/volume] in Serum or Plasma192mg/dL<=199 mg/dLNormalS
1705-04-21Cholesterol in HDL [Mass/volume] in Serum or Plasma52mg/dL>=40 mg/dLNormalS
1705-04-21Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation116mg/dLBelow 130NormalS
1705-04-21Triglyceride [Mass/volume] in Serum or Plasma120mg/dL<=149 mg/dLNormalS

Physical Exam

Vital signs recorded on 1705-04-21; see the Vital Signs section. [S]

SystemFinding
ConstitutionalWeathered, fit-looking man; weight 69.2 kg, BMI 22.6; blood pressure 120/76, pulse 64, temperature 36.6 C
EyesSclerae white; no pallor
NeckNo lymph node or thyroid enlargement
CardiovascularRegular rhythm; normal heart sounds; no murmur
RespiratoryClear to auscultation bilaterally
AbdomenSoft and non-tender; spleen not palpable
SkinSun-weathered face and hands; no suspicious lesions
PsychiatricAlert and engaged

Problems

ProblemClinical statusVerificationCodeProvenance
Recurrent episodes of fever with shaking chills and drenching sweats, three in the past two years, each beginning months after naval service in malaria-endemic areas; the first diagnosed as malaria abroad on a blood smear with the species not recorded and treated with chloroquine alone, the later two treated with chloroquine without testing; the last ended six weeks before intake; afebrile and well at intake; cause not established at intake; infectious diseases consultation requestedresolvedconfirmed R50.9S — Synthetic presenting problem anchored to his documented recurrent attacks of illness called malaria; superseded by the diagnosis at the infectious diseases consultation.
Relapsing Plasmodium vivax malaria: P. vivax DNA detected by PCR in blood drawn between attacks, with negative smears and rapid antigen test; after three relapses treated without antirelapse therapy; normal quantitative G6PDresolvedconfirmed B51.9S — Synthetic modern diagnosis made at the infectious diseases consultation, linked to his documented recurrent attacks of illness called malaria; the species and the PCR result are synthetic.
Pre-travel care for a naval deployment, expected to sail early next year, to French Guiana and the French Antilles: yellow fever vaccination required for entry to French Guiana, malaria prevention, dengue, chikungunya and typhus prevention by vector avoidance, food and water safety, and travel vaccinesactiveconfirmed Z71.84S — Synthetic modern counterpart of his documented preparation of a tropical campaign in 1705.

Assessment and Plan

Personalized prevention plan. A written copy was given to the patient. [S]

ServiceStatusDetail
Blood pressureCompleted today120/76 mmHg
Depression screeningCompleted todayPHQ-2 score 0
Tobacco useCompleted todayNever used tobacco
Unhealthy alcohol useCompleted todayAUDIT-C 3; brief advice given
Cholesterol and cardiovascular riskCompleted todayLDL cholesterol 116 mg/dL, HDL 52 mg/dL; no diabetes, smoking or hypertension; no statin indicated
Diabetes screeningNot indicatedBMI 22.6 with no other risk factor; glucose 92 mg/dL at intake
Colorectal cancer screeningNot indicatedBegins at 45; no family history recorded
HIV screeningOrderedOne-time screening for adults 15 to 65; drawn today with his agreement
Hepatitis C screeningOrderedOne-time antibody test for adults 18 to 79; drawn today
Hepatitis B screening and vaccinationOrderedOne-time triple panel drawn today; hepatitis B vaccine before the deployment if he is not immune
Tetanus, diphtheria, and pertussisCompleted todayTdap today; no dose recorded in the last ten years
Travel vaccinesDueYellow fever, hepatitis A and typhoid at the pre-travel visit, as the consultant advised
Influenza vaccineDueIn the autumn, before the deployment
Skin cancer counselingCompleted todaySun protection at sea discussed; hat and sunscreen

Immunizations given today: Tdap vaccine [S]

Guideline basis: Treatment of Uncomplicated Malaria (clinical guidance) (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Adult Immunization Schedule by Age (2026)

Follow-up: Pre-travel vaccine visit in the summer. Screening results through the patient portal. Next scheduled visit 1705-07-28: pre-travel visit: yellow fever, hepatitis A, hepatitis B and typhoid vaccines, and the travel plan. [S]

Advance Care Planning

Voluntary advance care planning discussion of about 20 minutes, with his consent, before a long deployment at sea far from hospital care. He named a health care agent and a second agent, and a health care proxy form was completed; both are recorded in the chart and are not named here. He wants full treatment if he is ill or injured, including evacuation to the nearest hospital. He asked for a short medical summary, including his malaria history and G6PD result, to carry with the ship's medical officer. The plan will be revisited before he sails. [S]